Twist Bioscience Corp (TWST) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026 (Q3 Fiscal 2026). Twist Bioscience Corporation provides customizable solutions across the biological continuum, utilizing a proprietary silicon-based platform for DNA synthesis, protein solutions, and next-generation sequencing (NGS) applications. The company serves over 3,800 customers in therapeutics, diagnostics, academic research, and industrial sectors.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Revenue | $118.4 million | $96.1 million | $332.8 million | $277.6 million |
| Gross Margin | 52.8% | 53.4% | 52.1% | 50.5% |
| Net Loss | $(35.1) million | $20.4 million (Income) | $(109.6) million | $(50.5) million |
| Operating Loss | $(36.3) million | $(30.1) million | $(115.0) million | $(106.3) million |
| Cash & Equivalents | $117.4 million | $183.0 million | $117.4 million | $183.0 million |
| Short-term Investments | $49.4 million | $49.4 million | $49.4 million | $49.4 million |
| Total Liquidity | $166.8 million | $232.4 million | $166.8 million | $232.4 million |
| Operating Cash Flow | N/A | N/A | $(41.3) million | $(35.8) million |
Note: Q3 2025 net income included a $48.8 million gain on the sale of the DNA data storage business, which did not recur in 2026.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 23% year-over-year in Q3 and 20% year-over-year YTD, driven by a 39% increase in DNA synthesis and protein solutions and a 12% increase in NGS applications.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 27% in Q3 and 24% YTD due to headcount additions and commercial infrastructure investments. Research and Development (R&D) expenses decreased 13% YTD, largely due to the prior year's sale of the DNA data storage business.
- Profitability: The company returned to a net loss in Q3 2026 compared to net income in Q3 2025, primarily due to the absence of the one-time gain on sale of business and increased operating expenses.
- Liquidity: Total cash and short-term investments decreased by approximately $65.6 million YTD, reflecting operating cash outflows and capital expenditures.
Guidance, Outlook, and Risks
- Strategic Investments: In February 2026, the company entered a $33.8 million commitment with Invenra Inc. for a license to the B-Body bispecific antibody discovery platform and a 6.24% equity stake. $5.0 million was paid in cash; the remainder was settled or is contingent on technology transfer via stock issuance.
- Capital Access: In June 2026, Twist established an At-The-Market (ATM) equity offering program with up to $200.0 million capacity. No shares have been sold as of June 30, 2026.
- Legal Contingencies: The company reached a settlement in principle for a securities class action lawsuit totaling approximately $17.1 million, with the majority expected to be funded by liability insurers. A derivative action settlement of approximately $1.0 million (insurer-funded) was also reached.
- Outlook: Management expects SG&A expenses to moderate in Q4 2026 due to cost-saving initiatives. The company believes current liquidity is sufficient to fund operations for at least 12 months.
Key Facts for Investor Verification
- Revenue Mix Shift: Verify the sustainability of the 39% growth in DNA synthesis and protein solutions versus the 12% growth in NGS applications.
- SG&A Trajectory: Monitor the effectiveness of cost-saving initiatives to moderate SG&A expenses in Q4 2026 as projected by management.
- Litigation Resolution: Confirm the final court approval of the $17.1 million securities class action settlement and the extent of insurance coverage.
- Invenra Integration: Track the progress of the technology transfer for the Invenra license, which triggers the issuance of $5.0 million in contingent stock.
- Cash Burn Rate: Assess the runway provided by the $166.8 million liquidity position against the current operating cash burn of approximately $41.3 million per nine months.